Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes

Anna Ludovica Fracanzani, Luca Valenti, Elisabetta Bugianesi, Marco Andreoletti, Agostino Colli, Ester Vanni, Cristina Bertelli, Erika Fatta, Daniela Bignamini, Giulio Marchesini, Silvia Fargion – 30 May 2008 – It is uncertain whether patients with nonalcoholic fatty liver disease (NAFLD) and normal alanine aminotransferase (ALT) have a milder disease and should undergo liver biopsy.

The genetic background modulates susceptibility to mouse liver Mallory‐Denk body formation and liver injury

Shinichiro Hanada, Pavel Strnad, Elizabeth M. Brunt, M. Bishr Omary – 30 May 2008 – Mallory‐Denk bodies (MDBs) are hepatocyte inclusions found in several liver diseases and consist primarily of keratins 8 and 18 (K8/K18) and ubiquitin that are cross‐linked by transglutaminase‐2. We hypothesized that genetic variables contribute to the extent of MDB formation, because not all patients with an MDB‐associated liver disease develop inclusions.

Long‐term outcome of human leukocyte antigen mismatching in liver transplantation: Results of the national institute of diabetes and digestive and kidney diseases liver transplantation database

Vijayan Balan, Kris Ruppert, A. Jake Demetris, Tatiana Ledneva, Rene J. Duquesnoy, Katherine M. Detre, Yuling L. Wei, Jorge Rakela, Daniel F. Schafer, John P. Roberts, James E. Everhart, Russell H. Wiesner – 30 May 2008 – A perfect or nearly perfect human leukocyte antigen (HLA) match has been associated with better immediate and long‐term survival of diseased donor kidney transplants. However, the effect of HLA matching for hepatic allografts remains poorly defined.

Biochemical response to ursodeoxycholic acid and long‐term prognosis in primary biliary cirrhosis

Christophe Corpechot, Ludovico Abenavoli, Nabila Rabahi, Yves Chrétien, Tony Andréani, Catherine Johanet, Olivier Chazouillères, Raoul Poupon – 30 May 2008 – Biochemical response to ursodeoxycholic acid (UDCA) in patients with primary biliary cirrhosis (PBC) is variable. It has been recently proposed that an alkaline phosphatase (ALP) decline of more than 40% in baseline value or a normal level after 1 year of UDCA treatment (Barcelona criteria) could serve as a good marker of long‐term prognosis.

Subscribe to